Nutrition 21 Announces Plans to Assist Government Agencies to Further Confirm Safety of Chromium Picolinate

PURCHASE, N.Y.--(BW HealthWire)--July 26, 2002--Nutrition 21 (NASDAQ: NXXI), Gail Montgomery, President and CEO of Nutrition 21 announced today that the Company plans to provide data on the safety of chromium picolinate to the Institute of Medicine (IOM) for its planned investigation of the safety of several widely used dietary supplements.

"Since our company believes that the dietary supplement industry should be held to very high standards, we have already made a substantial investment in conducting toxicology studies and clinical research to support our product and label claims, and have sought third party confirmation of our findings. Recently, after careful review of an extensive dossier of safety data that was compiled by ENVIRON, a pre-eminent science and regulatory consultant group, an independent panel of experts approved Chromax(R) chromium picolinate as generally recognized as safe for use in foods (GRAS)," said Ms. Montgomery.

ENVIRON's stringent review process confirmed the findings of our earlier safety studies, which along with more than a decade of consumer experience, gives us confidence the IOM will reach the same conclusions. Additional government studies are welcome as we expect that they will dispel any remaining doubts as to the safety of chromium picolinate. Once the safety profile has been confirmed by governmental regulatory experts, we believe the substantial body of evidence demonstrating chromium picolinate's ability to positively impact insulin sensitivity, will result in wide scale adoption of its use as a safe, cost effective nutritional therapy for people with insulin resistance," concluded Montgomery.

Insulin resistance, which results in poor blood sugar control, is thought to be an underlying problem in people with diabetes and obesity and has been observed as a metabolic problem in people with Syndrome X, a condition some health experts consider to be a pre-cursor to diabetes. Syndrome X is estimated to affect as many as one in five Americans. Nutrition 21's flagship product, Chromax chromium picolinate has already been shown to improve blood sugar control in ten clinical studies involving more than 1,300 people with diabetes.

About Nutrition 21

Nutrition 21 is a leading developer and marketer of nutritional products whose health benefits are substantiated by clinical research. The Company is the market leader in nutritional chromium, and currently holds 35 patents for nutrition products, 22 of which are for chromium compounds and their uses. Visit

Safe Harbor Provision

The words "believe", "expect", "anticipate" and other similar expressions generally identify forward-looking statements. Forward-looking statements are based on the company's current expectations and are subject to market, competitive and regulatory factors and the other risks and uncertainties indicated from time to time in the company's filings with the Securities and Exchange Commission. Actual results can differ materially. The company makes no commitment to disclose any revisions to forward-looking statements.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.